Kappos L - Search Results

1

Impact of complement activation on clinical outcomes in multiple sclerosis.

Keller CW, Oechtering J, Wiendl H, Kappos L, Kuhle J, Lünemann JD. Keller CW, et al. Among authors: kappos l. Ann Clin Transl Neurol. 2021 Apr;8(4):944-950. doi: 10.1002/acn3.51334. Epub 2021 Mar 1. Ann Clin Transl Neurol. 2021. PMID: 33646629 Free PMC article.

2

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Miller DH, et al. Among authors: kappos l. J Neurol Neurosurg Psychiatry. 1991 Aug;54(8):683-8. doi: 10.1136/jnnp.54.8.683. J Neurol Neurosurg Psychiatry. 1991. PMID: 1940938 Free PMC article.

3

Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study.

Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P, Malin JP, Fierz W, Graffenried BU, Gugerli US. Kappos L, et al. Ann Neurol. 1988 Jan;23(1):56-63. doi: 10.1002/ana.410230110. Ann Neurol. 1988. PMID: 3278672 Clinical Trial.

4

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.

Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH. Filippi M, et al. Among authors: kappos l. Neurology. 1995 Feb;45(2):255-60. doi: 10.1212/wnl.45.2.255. Neurology. 1995. PMID: 7854522 Clinical Trial.

5

[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment].

Wiendl H, Neuhaus O, Kappos L, Hohlfeld R. Wiendl H, et al. Among authors: kappos l. Nervenarzt. 2000 Aug;71(8):597-610. doi: 10.1007/s001150050636. Nervenarzt. 2000. PMID: 10996910 Free PMC article. Review. German.

6

Visual and motor evoked potentials in the course of multiple sclerosis.

Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Fuhr P, et al. Among authors: kappos l. Brain. 2001 Nov;124(Pt 11):2162-8. doi: 10.1093/brain/124.11.2162. Brain. 2001. PMID: 11673318 Clinical Trial.

7

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.

Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F; European Study Group in Interferon beta-1b in Secondary-Progressive MS. Kappos L, et al. Neurology. 2001 Dec 11;57(11):1969-75. doi: 10.1212/wnl.57.11.1969. Neurology. 2001. PMID: 11739811 Clinical Trial.

8

Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis.

Pache M, Kaiser HJ, Akhalbedashvili N, Lienert C, Dubler B, Kappos L, Flammer J. Pache M, et al. Among authors: kappos l. Eur Neurol. 2003;49(3):164-8. doi: 10.1159/000069085. Eur Neurol. 2003. PMID: 12646761

9

Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.

Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans-Coutinho M, Clanet M, Radue EW, Kappos L; European rIFN beta-1a in Relapsing MS Dose Comparison Trial Study Group. Hardmeier M, et al. Among authors: kappos l. Arch Neurol. 2003 Dec;60(12):1736-9. doi: 10.1001/archneur.60.12.1736. Arch Neurol. 2003. PMID: 14676048

10

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW. Kappos L, et al. J Neurol. 2004 Sep;251 Suppl 5:v57-v64. doi: 10.1007/s00415-004-1509-6. J Neurol. 2004. PMID: 15549357 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

807 results

Search Page

Filters